Intradermal Injection of a Tat Oyi-based Therapeutic HIV Vaccine Reduces of 1.5 Log Copies/mL the HIV RNA Rebound Median and No HIV DNA Rebound Following CART Interruption in a Phase I/II Randomized Controlled Clinical Trial

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2016 Apr 3

PMID 27036656

Citations 12

Authors

Erwann P Loret

Albert Darque

Elisabeth Jouve

Elvenn A Loret

Corinne Nicolino-Brunet

Sophie Morange

Elisabeth Castanier

Josiane Casanova

Christine Caloustian

Charleric Bornet

Julie Coussirou

Jihen Boussetta

Vincent Couallier

Olivier Blin

Bertrand Dussol

Isabelle Ravaux

Affiliations

Soon will be listed here.

Abstract

Background: A Tat Oyi vaccine preparation was administered with informed consent to 48 long-term HIV-1 infected volunteers whose viral loads had been suppressed by antiretroviral therapy (cART). These volunteers were randomized in double-blind method into four groups (n = 12) that were injected intradermally with 0, 11, 33, or 99 µg of synthetic Tat Oyi proteins in buffer without adjuvant at times designated by month 0 (M0), M1 and M2, respectively. The volunteers then underwent a structured treatment interruption between M5 and M7.

Results: The primary outcomes of this phase I/IIa clinical trial were the safety and lowering the extent of HIV RNA rebound after cART interruption. Only one undesirable event possibly due to vaccination was observed. The 33 µg dose was most effective at lowering the extent of HIV RNA and DNA rebound (Mann and Whitney test, p = 0.07 and p = 0.001). Immune responses against Tat were increased at M5 and this correlated with a low HIV RNA rebound at M6 (p = 0.01).

Conclusion: This study suggests in vivo that extracellular Tat activates and protects HIV infected cells. The Tat Oyi vaccine in association with cART may provide an efficient means of controlling the HIV-infected cell reservoir.

Citing Articles

Role of HIV-1 Tat Protein Interactions with Host Receptors in HIV Infection and Pathogenesis.

Cafaro A, Schietroma I, Sernicola L, Belli R, Campagna M, Mancini F Int J Mol Sci. 2024; 25(3).

PMID: 38338977 PMC: 10855115. DOI: 10.3390/ijms25031704.

New insights into pathogenesis point to HIV-1 Tat as a key vaccine target.

Ensoli B, Moretti S, Borsetti A, Maggiorella M, Butto S, Picconi O Arch Virol. 2021; 166(11):2955-2974.

PMID: 34390393 PMC: 8363864. DOI: 10.1007/s00705-021-05158-z.

Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs.

Tunggal H, Munson P, OConnor M, Hajari N, Dross S, Bratt D PLoS One. 2021; 16(6):e0253265.

PMID: 34138927 PMC: 8211199. DOI: 10.1371/journal.pone.0253265.

The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation.

Nicoli F, Gallerani E, Sicurella M, Pacifico S, Cafaro A, Ensoli B Vaccines (Basel). 2020; 8(2).

PMID: 32512757 PMC: 7349931. DOI: 10.3390/vaccines8020274.

Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.

Jin H, Li D, Lin M, Li L, Harrich D Viruses. 2020; 12(4).

PMID: 32276443 PMC: 7232260. DOI: 10.3390/v12040415.

References

Cary D, Fujinaga K, Peterlin B . Molecular mechanisms of HIV latency. J Clin Invest. 2016; 126(2):448-54. PMC: 4731164. DOI: 10.1172/JCI80565. View

Yukl S, Boritz E, Busch M, Bentsen C, Chun T, Douek D . Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013; 9(5):e1003347. PMC: 3649997. DOI: 10.1371/journal.ppat.1003347. View

Rolland M, Edlefsen P, Larsen B, Tovanabutra S, Sanders-Buell E, Hertz T . Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012; 490(7420):417-20. PMC: 3551291. DOI: 10.1038/nature11519. View

Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

Deng K, Pertea M, Rongvaux A, Wang L, Durand C, Ghiaur G . Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015; 517(7534):381-5. PMC: 4406054. DOI: 10.1038/nature14053. View

Chun T, Nickle D, Justement J, Meyers J, Roby G, Hallahan C . Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008; 197(5):714-20. DOI: 10.1086/527324. View

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O . HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology. 2015; 12:33. PMC: 4414440. DOI: 10.1186/s12977-015-0151-y. View

Assoumou L, Weiss L, Piketty C, Burgard M, Melard A, Girard P . A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control. AIDS. 2015; 29(15):2003-7. DOI: 10.1097/QAD.0000000000000734. View

Goldstein G, Damiano E, Donikyan M, Pasha M, Beckwith E, Chicca J . HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation: HIV rebound with current ART appears to be due to infection with new endogenous founder virus and not to resurgence of pre-existing Tat-dependent.... Hum Vaccin Immunother. 2012; 8(10):1425-30. PMC: 3660761. DOI: 10.4161/hv.21616. View

10.

Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B . Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984; 224(4648):500-3. DOI: 10.1126/science.6200936. View

11.

Opi S, Peloponese Jr J, Esquieu D, Campbell G, de Mareuil J, Walburger A . Tat HIV-1 primary and tertiary structures critical to immune response against non-homologous variants. J Biol Chem. 2002; 277(39):35915-9. DOI: 10.1074/jbc.M204393200. View

12.

Hellmuth J, Valcour V, Spudich S . CNS reservoirs for HIV: implications for eradication. J Virus Erad. 2015; 1(2):67-71. PMC: 4586130. View

13.

Mediouni S, Jablonski J, Paris J, Clementz M, Thenin-Houssier S, McLaughlin J . Didehydro-cortistatin A inhibits HIV-1 Tat mediated neuroinflammation and prevents potentiation of cocaine reward in Tat transgenic mice. Curr HIV Res. 2015; 13(1):64-79. PMC: 4416414. DOI: 10.2174/1570162x13666150121111548. View

14.

Persaud D, Gay H, Ziemniak C, Chen Y, Piatak Jr M, Chun T . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369(19):1828-35. PMC: 3954754. DOI: 10.1056/NEJMoa1302976. View

15.

Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E . Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2010; 117(10):2791-9. DOI: 10.1182/blood-2010-09-309591. View

16.

Hurst J, Hoffmann M, Pace M, Williams J, Thornhill J, Hamlyn E . Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015; 6:8495. PMC: 4633715. DOI: 10.1038/ncomms9495. View

17.

Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M . Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995; 373(6510):123-6. DOI: 10.1038/373123a0. View

18.

El-Sadr W, Lundgren J, Neaton J, Gordin F, Abrams D, Arduino R . CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-96. DOI: 10.1056/NEJMoa062360. View

19.

Mediouni S, Darque A, Ravaux I, Baillat G, Devaux C, Loret E . Identification of a highly conserved surface on Tat variants. J Biol Chem. 2013; 288(26):19072-80. PMC: 3696680. DOI: 10.1074/jbc.M113.466011. View

20.

Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C . The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology. 2014; 11:49. PMC: 4087126. DOI: 10.1186/1742-4690-11-49. View